Speech-to-text Tool for Heart Failure Patient-Reported Data
Part of paid clinical trials in Palo Alto, California.
- Sponsor
- Stanford University
- Study ID
- NCT07217366
- Status
- Enrolling By Invitation
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Artificial intelligence speech-to-text tool — OTHERPilot testing of speech-to-text tool using artificial intelligence
Study Details
The goal of this study is to see whether this type of Artificial Intelligence (AI) Voice Assistant can reliably capture patient-reported health information to support communication between patients and their healthcare team.
Key Dates
- Start date
- Oct 13, 2025
- Status verified
- Mar 2026
- Primary completion
- May 31, 2026
- Completion
- Jun 30, 2026
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DIAGNOSTIC
Arms
- Experimental: AI Voice AssistantParticipants in the AI Voice Assistant arm will complete two activities: (1) an interaction with the AI Voice Assistant tool and (2) Paper survey that includes the same questions asked by AI voice assistant. Half of the participants will use the AI Voice Assistant first, while the other half will begin with the paper survey.
Primary Outcome Measure
Accuracy of AI Voice Assistant Compared With Expert Extraction [ Time Frame: ~3 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Stanford University | Palo Alto | California | 94304 | - |
Find similar trials in Palo Alto, CA
By condition
By specialty
By research site
Related Studies
- Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy ProductsRecruiting · Medtronic · Birmingham, Alabama
- The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMRRecruiting · Cardiac Dimensions, Inc. · Gilbert, Arizona
- Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart RecipientsPHASE2 · Recruiting · Baylor Research Institute · Los Angeles, California
- Metformin for Pulmonary Hypertension HFpEFPHASE2 · Recruiting · University of California, San Francisco · San Francisco, California